These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 9540761)

  • 1. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients.
    Behre G; Link H; Maschmeyer G; Meyer P; Paaz U; Wilhelm M; Hiddemann W
    Ann Hematol; 1998 Feb; 76(2):73-80. PubMed ID: 9540761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy.
    Hung KC; Chiu HH; Tseng YC; Wang JH; Lin HC; Tsai FJ; Peng CT
    J Microbiol Immunol Infect; 2003 Dec; 36(4):254-9. PubMed ID: 14723254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients: a randomized study.
    de la Cámara R; Figuera A; Sureda A; Hermida G; Verge G; Olalla I; Fernández Rañada JM; Domingo Albos A
    Haematologica; 1997; 82(6):668-75. PubMed ID: 9580087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial.
    Feld R; DePauw B; Berman S; Keating A; Ho W
    J Clin Oncol; 2000 Nov; 18(21):3690-8. PubMed ID: 11054442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. The Meropenem Study Group of Leuven, London and Nijmegen.
    J Antimicrob Chemother; 1995 Jul; 36(1):185-200. PubMed ID: 8537265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey.
    Agaoglu L; Devecioglu O; Anak S; Karakas Z; Yalman N; Biner B; Eryilmaz E; Goksan B; Unuvar A; Agirbasli H; Can M; Bilgen H; Gedikoglu G
    J Chemother; 2001 Jun; 13(3):281-7. PubMed ID: 11450887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group.
    Cordonnier C; Herbrecht R; Pico JL; Gardembas M; Delmer A; Delain M; Moreau P; Ladeb S; Nalet V; Rollin C; Gres JJ
    Clin Infect Dis; 1997 Jan; 24(1):41-51. PubMed ID: 8994754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey.
    Akova M; Akan H; Korten V; Biberoğlu K; Hayran M; Unal S; Kars A; Kansu E
    Int J Antimicrob Agents; 1999 Sep; 13(1):15-9. PubMed ID: 10563400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program.
    Cometta A; Calandra T; Gaya H; Zinner SH; de Bock R; Del Favero A; Bucaneve G; Crokaert F; Kern WV; Klastersky J; Langenaeken I; Micozzi A; Padmos A; Paesmans M; Viscoli C; Glauser MP
    Antimicrob Agents Chemother; 1996 May; 40(5):1108-15. PubMed ID: 8723449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients.
    Rolston KV; Berkey P; Bodey GP; Anaissie EJ; Khardori NM; Joshi JH; Keating MJ; Holmes FA; Cabanillas FF; Elting L
    Arch Intern Med; 1992 Feb; 152(2):283-91. PubMed ID: 1739355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with three combination regimens for the treatment of high-risk febrile neutropenia.
    Serefhanoglu K; Ersoy Y; Serefhanoglu S; Aydogdu I; Kuku I; Kaya E
    Ann Acad Med Singap; 2006 Jan; 35(1):11-6. PubMed ID: 16470268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinafloxacin monotherapy (CI-960) versus ceftazidime plus amikacin for empirical treatment of febrile neutropenic cancer patients.
    Glauser MP; Brennscheidt U; Cornely O; Grigg A; Figuera A; Keyserling C; Trostmann U; Welling L; Tack K
    Clin Microbiol Infect; 2002 Jan; 8(1):14-25. PubMed ID: 11906496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients].
    Pérez C; Sirham M; Labarca J; Grebe G; Lira P; Oliva J; Duhalde M; Ocqueteau M; Acuña G
    Rev Med Chil; 1995 Mar; 123(3):312-20. PubMed ID: 8525170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients.
    Flaherty JP; Waitley D; Edlin B; George D; Arnow P; O'Keefe P; Weinstein RA
    Am J Med; 1989 Nov; 87(5A):278S-282S. PubMed ID: 2686429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer.
    Fleischhack G; Hartmann C; Simon A; Wulff B; Havers W; Marklein G; Hasan C; Bode U
    J Antimicrob Chemother; 2001 Jun; 47(6):841-53. PubMed ID: 11389117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group.
    Mouton YJ; Beuscart C
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():145-56. PubMed ID: 8543490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients.
    Aparicio J; Oltra A; Llorca C; Montalar J; Herranz C; Gómez-Codina J; Pastor M; Munárriz B
    Eur J Cancer; 1996 Sep; 32A(10):1739-43. PubMed ID: 8983283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
    Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program.
    Menichetti F; Martino P; Bucaneve G; Gentile G; D'Antonio D; Liso V; Ricci P; Nosari AM; Buelli M; Carotenuto M
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2041-6. PubMed ID: 7811016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empiric monotherapy in neutropenia: a realistic goal?
    Del Favero A; Bucaneve G; Menichetti F
    Scand J Infect Dis Suppl; 1995; 96():34-7. PubMed ID: 7652501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.